Answers are grounded in this paper and cite their sources.
Most studies on the HIV reservoir have focused on resting memory CD4+ T cells. This focus has shaped how researchers think about viral persistence and has guided the development of “shock-and-kill” strategies. But new research shows the reservoir is much broader. It includes myeloid, stromal, and non-immune cells, each with its own ways of maintaining viral latency. Macrophages, microglia, and dendritic cells can carry replication-competent HIV. Different epigenetic mechanisms and transcription factors regulate their proviruses, highlighting the need to determine whether cure strategies designed primarily for T cells can also address these reservoirs. The reservoir is also shaped by its location in the body. The brain, gut, and liver each create different challenges for persistence and treatment, challenges that cannot be explained just by cell type. We argue that the HIV reservoir is not a single entity. Instead, it is a collection of unique latency programs in different cells and tissues. Ignoring this complexity is a major gap in current cure research. To make progress, we need to map the reservoir’s true distribution, use the right assays for each cell type, and design drugs and therapies that match this diversity.
No takes yet. Share an insight, caveat, or question.
Setubi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: